NBIX director receives new option and RSU awards

NEUROCRINE BIOSCIENCES INC director Gary A. Lyons received new equity awards as part of his compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC director Gary A. Lyons received new equity awards as part of his compensation. On May 27, 2026, he was granted non-qualified stock options for 2,624 shares of common stock at an exercise price of $155.83 per share, vesting in 12 monthly installments beginning June 27, 2026.

He also received 1,284 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs will vest in full on May 27, 2027. The filing shows these as direct holdings and reflects routine, compensation-related acquisitions rather than open-market buying or selling.

Insider Trade Summary

Grant/Award: 3,908 shares

Grant/Award 2 txns

Insider LYONS GARY A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	1,284	$0.00	$0.00
Grant/Award	Non-Qualified Stock Option	2,624	$0.00	$0.00

Holdings After Transaction: Restriced Stock Unit — 1,284 contracts (Direct); Non-Qualified Stock Option — 2,624 contracts (Direct)

Footnotes (3)

F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2. The RSUs will vest in full on May 27, 2027.
F3. Option vests in 12 monthly installments beginning June 27, 2026.

Key Figures

Stock options granted: 2,624 options Option exercise price: $155.83 per share RSUs granted: 1,284 RSUs +5 more

8 metrics

Stock options granted 2,624 options Non-qualified stock option grant on May 27, 2026

Option exercise price $155.83 per share Exercise price for newly granted options

RSUs granted 1,284 RSUs Restricted Stock Unit grant on May 27, 2026

Option vesting start June 27, 2026 First of 12 monthly vesting installments

Option expiration May 27, 2036 Expiration date for non-qualified stock options

RSU vesting date May 27, 2027 Cliff vesting date when RSUs vest in full

Options held after grant 2,624 options Total options reported following transaction

RSUs held after grant 1,284 RSUs Total RSUs reported following transaction

Key Terms

Non-Qualified Stock Option, Restricted Stock Unit, vest, exercise price, +1 more

5 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option grant for 2,624 shares at $155.83 per share"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vest financial

"The RSUs will vest in full on May 27, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price": "155.8300" for the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant/award acquisition financial

"transaction_action": "grant/award acquisition" for both equity awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did NBIX director Gary A. Lyons receive in this Form 4?

Gary A. Lyons received non-qualified stock options for 2,624 shares and 1,284 Restricted Stock Units. Both awards relate to Neurocrine Biosciences common stock and are classified as compensation-related grants, not open-market purchases or sales.

What are the vesting terms of Gary Lyons’ Neurocrine (NBIX) stock options?

The non-qualified stock options for 2,624 shares have an exercise price of $155.83 per share. They vest in 12 equal monthly installments starting June 27, 2026, providing a one-year vesting schedule after the grant date.

When do Gary Lyons’ Restricted Stock Units in NBIX fully vest?

The 1,284 Restricted Stock Units granted to Gary Lyons vest in full on May 27, 2027. Each RSU represents the right to receive one share of Neurocrine Biosciences common stock upon vesting, according to the filing footnotes.

Does this NBIX Form 4 show Gary Lyons buying or selling stock on the market?

No, the Form 4 reports compensation-related grants, not market trades. Both the stock options and RSUs are coded as awards or other acquisitions, with no open-market purchase or sale transactions disclosed in this filing.

What exercise price is attached to Gary Lyons’ newly granted NBIX stock options?

The non-qualified stock options carry an exercise price of $155.83 per share. This is the price at which Gary Lyons can purchase Neurocrine Biosciences common stock if he exercises the options after they vest.

How many NBIX shares underlie Gary Lyons’ new options and RSUs combined?

The filing shows 2,624 underlying shares for the non-qualified stock options and 1,284 underlying shares for the Restricted Stock Units. Together, the new awards cover 3,908 shares of Neurocrine Biosciences common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/29/2026 - 06:04 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LYONS GARY A

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restriced Stock Unit⁽¹⁾	$0	05/27/2026		A		1,284		⁽²⁾	⁽²⁾	Common Stock	1,284	$0	1,284	D
Non-Qualified Stock Option	$155.83	05/27/2026		A		2,624		⁽³⁾	05/27/2036	Common Stock	2,624	$0	2,624	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

3. Option vests in 12 monthly installments beginning June 27, 2026.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR